ClinConnect ClinConnect Logo
Search / Trial NCT00248378

Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis

Launched by CENTER FOR MEDICINAL CANNABIS RESEARCH · Nov 2, 2005

Trial Information

Current as of June 09, 2025

Completed

Keywords

Multiple Sclerosis Cannabis Spasticity Tolerability

ClinConnect Summary

Studies of cannabinoids for spasticity in MS have had mixed results but clinical studies have been small, generally not properly controlled, with results controversial, and difficult to interpret. Recently, investigators in the UK and US tested the ability of cannabinoids to control spasticity and tremor symptoms of the MS-like disease, experimental allergic encephalomyelitis, in mice (Baker et al, 2000). The authors found that four different cannabinoids quantitatively ameliorated both tremor and spasticity in diseased mice; thus providing rationale for patients' reports of the therapeutic...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Clinically definite or probable, laboratory-supported MS
  • Complaints of spasticity and at least moderate increase in tone as evidenced by a score of \>= 2 on the Modified Ashworth Scale at either the elbow, hip, or knee
  • If on disease-modifying therapy ("ABC"), have been on a stable dose for at least six months
  • Fluent in English
  • If not cannabis-naive, must refrain from smoking cannabis for two weeks prior to screening (confirmed by urinalysis)
  • If on either lioresal (Baclofen) or tizanadine (Zanaflex), have been on a stable dose for at least three months
  • \>=18 years of age
  • Exclusion Criteria:
  • Axis I psychiatric disorder especially depression or significant neurological disease other than MS as determined by the PI
  • Recent history of active substance abuse defined as daily use for at least 14 days within the past month
  • Drug use restrictions, eg, subjects on probation or parole, employment involving high risk to themselves and/or the public (airline pilot, bus driver, etc.)
  • Any unstable medical health problem
  • Any known pulmonary disorders, including tuberculosis, asthma, or COPD
  • Pregnant or nursing
  • Require benzodiazepines to control spasticity
  • Require high doses of analgesic medications on a daily basis

About Center For Medicinal Cannabis Research

The Center for Medicinal Cannabis Research (CMCR) is a leading research institution dedicated to advancing the understanding and therapeutic applications of cannabis-based treatments. Focused on rigorous scientific investigation, CMCR conducts clinical trials to evaluate the safety, efficacy, and potential benefits of medicinal cannabis for various medical conditions. By fostering collaboration among researchers, healthcare professionals, and policymakers, the Center aims to provide evidence-based insights that inform clinical practice and guide regulations surrounding medicinal cannabis use. With a commitment to integrity and innovation, CMCR plays a pivotal role in shaping the future of cannabinoid medicine.

Locations

San Diego, California, United States

Patients applied

0 patients applied

Trial Officials

Jody Corey-Bloom, M.D., Ph.D.

Principal Investigator

University of California, San Diego

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials